Labcorp’s Post

Paul W. Noble, MD, discusses key unmet needs in idiopathic pulmonary fibrosis therapies in this K-Cast series. They highlight the potential for novel treatments to optimize patient outcomes and discuss how the GAP model can help determine patient prognosis. Watch the program here to learn more: https://bit.ly/3VYeOSZ #ManagedCare

A call for precision and objectivity in clinical care, particularly in biomarker discovery and recovery for active and aging patient populations. Too often, we capture patient-specific data only after significant functional deterioration. Without prior baseline measures or benchmark data, this information lacks the necessary impact. Every clinical setting, both traditional and digital, should prioritize objective measures and have the tools to consistently collect stable biomarkers, such as grip strength and gait, to improve patient outcomes. #ClinicalCare #Biomarkers #PatientOutcomes #DigitalHealth #ObjectiveData #HealthcareInnovation #AgingPopulation #PrecisionMedicine

🔬 The Power of Biomarker Testing in Advancing Health 🔬 As we navigate the complexities of modern healthcare, biomarker testing is a pivotal tool in our mission to improve patient outcomes and advance personalized medicine. At the Cholangiocarcinoma Foundation, we believe in this technology's transformative potential. Biomarker testing enables tailored treatment plans, leading to better health outcomes for our community. It's not just about identifying diseases—it's about understanding them at a molecular level to provide the most effective care possible. #Cholangiocarcinoma survivor Matt Reidy shares his story about how biomarker testing changed his course of treatment after he found out he had the MLH1 mutation. There is hope in research. Matt's story: https://lnkd.in/gAPm9k8f #HealthcareInnovation #BiomarkerTesting #PrecisionMedicine #BiomarkersMatter #CureCCA #CCAHope

This proof-of-concept observational study shows that dd-cfDNA, a noninvasive biomarker for rejection risk, can be used to help inform physician decisions regarding IST reduction in KTx patients, along with patient evaluation and other clinical factors. #OpenAccess tinyurl.com/45s8sr9z

Unlocking the future of patient care starts with tackling subclinical rejection. In this panel, we dive into the promising directions for biomarker research. Discover key insights into addressing this essential challenge—watch the full discussion here: https://ow.ly/iVUJ50U0FJ6 #SubclinicalRejection #KidneyHealth #TransplantInnovation

🔬 Explore evolving treatments for NSCLC with HER2 mutations. 💡 Gain confidence in interpreting biomarker results, personalizing care plans, and addressing barriers to ensure seamless patient care. Learn more: http://ms.spr.ly/6047WNuU7 #NSCLC #PrecisionMedicine

Did you know that someone dies every three seconds from organ failure due to sepsis? Early detection is critical to saving lives. At Teledyne, we’re working with Canatu to develop a high-sensitivity multiplexing bio-sensing platform that can rapidly detect sepsis biomarkers and help predict organ failure. Want to learn more? Join us at MEDICA 2024 at Booth 8A N40, where we’ll be sharing insights into this technology and its potential to change patient care. #MEDICA2024 #TeledyneHealthcare #SepsisDetection Carsten Gollasch, PhD, MBA Caterina Taddei Mari Makkonen

🫀Gone are the days of complicated procedures – simply add the sample, and the test takes care of the rest！🧪🔬 💡Elevate your cardiac care with Biotime cutting-edge 3-in-1 (cTnI/CK-MB/Myo) Rapid Quantitative Test. Designed with the clinician in mind, this innovative solution streamlines the diagnostic process and delivers unparalleled accuracy.✅ Remarkably, our test requires a low sample volume, allowing you to process whole blood without the need for centrifugation. This convenience factor not only saves time but also enhances patient comfort.✅ But the true power of this test lies in its comprehensive approach. By simultaneously detecting cTnI, CK-MB, and Myoglobin, our 3-in-1 solution provides unparalleled sensitivity and accuracy. This holistic assessment helps to reduce the risk of misdiagnosis caused by the narrow detection window of individual biomarkers.🙌🏻 🔗：https://lnkd.in/gCn7HArC #cardiacmarker #Myo #Myoglobin #cTnI #rapidtesting #quantitativetest #fia #CKMB #sensitivity #accuracy #biomarkers #FluorescentImmunoassay #diagnosis

Excited to share this post featuring Professor Angela Dispenzieri, about the benefits of Mass Spectrometry.

What are the clinical outcomes of Isa-KRd treatment in high-risk newly diagnosed #multiplemyeloma? Read our summary of the results from the phase II GMMG-CONCEPT trial to learn more! https://loom.ly/d3jmIlg #MMsm #myeloma #MedicalEducation